The intravascular lithotripsy market has undergone high growth trailblazed by J&J subsidiary Shockwave Medical.

Abbott received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system.

Boston Scientific announced via social media that it has closed the acquisition of Bolt Medical, which recently gained FDA ...

Boston Scientific received FDA clearance for its Bolt intravascular lithotripsy (IVL) system, according to the FDA's 510(k) ...

Clinical findings from the FORWARD PAD investigational device exemption (IDE) trial showed that Shockwave Javelin has an effectiveness and safety profile comparable to existing balloon-based IVL ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

Physicians often use several therapy approaches to clear calcified arterial blockages, including cutting balloons and atherectomy technology. IVL is a newer treatment for calcified coronary ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...